Elekta AB (publ) (OTCMKTS:EKTAY) Releases Earnings Results, Misses Expectations By $0.01 EPS

Elekta AB (publ) (OTCMKTS:EKTAY) released its quarterly earnings results on Friday. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01), Zacks reports. Elekta AB (publ) had a net margin of 5.65% and a return on equity of 11.07%.

Elekta AB (publ) Stock Up 0.4 %

EKTAY traded up $0.03 on Friday, hitting $6.09. 1,474 shares of the company were exchanged, compared to its average volume of 4,729. The firm has a 50-day moving average price of $5.72 and a two-hundred day moving average price of $6.09. The company has a current ratio of 1.05, a quick ratio of 0.81 and a debt-to-equity ratio of 0.60. Elekta AB has a twelve month low of $5.25 and a twelve month high of $8.24. The company has a market cap of $2.34 billion, a price-to-earnings ratio of 24.36 and a beta of 1.22.

Elekta AB (publ) Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Thursday, March 27th. Stockholders of record on Friday, March 7th will be paid a $0.1072 dividend. The ex-dividend date is Friday, March 7th. Elekta AB (publ)’s payout ratio is currently 48.00%.

Analysts Set New Price Targets

Separately, Sanford C. Bernstein upgraded Elekta AB (publ) from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 29th.

About Elekta AB (publ)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.